History | Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (MSWord 21 KB)

Published:

19 December 2018

Declaration of interests

Register of interests (PDF 135 KB)

Published:

03 April 2019

Final appraisal determination

Final appraisal determination
Final appraisal determination document (MSWord 51 KB)

Published:

08 November 2018
Committee papers (PDF 1.96 MB)

Published:

08 November 2018
Public committee slides (PowerPoint 770 KB)

Published:

08 November 2018

Draft guidance

Draft guidance
Appraisal consultation document (PDF 417 KB)

Published:

23 August 2018
Committee papers (PDF 10.06 MB)

Published:

23 August 2018
Public committee slides (PDF 973 KB)

Published:

23 August 2018

Invitation to participate

Final scope (PDF 229 KB)

Published:

21 February 2018
Final matrix (PDF 258 KB)

Published:

21 February 2018
Draft scope and provisional matrix comments table (post-referral) (PDF 381 KB)

Published:

21 February 2018
Equality impact assessment (Scoping) (PDF 176 KB)

Published:

21 February 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 323 KB)

Published:

25 August 2017
Draft matrix post referral (PDF 259 KB)

Published:

25 August 2017